---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-115424"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:26:38.086546+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma Q3 2022: YUPELRI sales up 35% YoY; $1.1B TRELEGY deal closed; debt-free

## Summary
- Implied 35% share of YUPELRI net sales $18.7M, up 35% YoY; Viatris collaboration revenue $12.4M.
- Closed TRELEGY royalty sale to Royalty Pharma for ~$1.1B upfront; gain of $1.14B; now debt-free with $486.8M cash.
- Initiated $250M capital return; purchased GSK's 9.6M shares at $9.75/shr; Dutch tender up to $95M extended to Nov 17.
- Operating expenses guidance: R&D $45-55M, SG&A $35-45M for FY2022 (excl. share-based comp and one-time costs).
- Ampreloxetine Phase 3 study (CYPRESS) in MSA patients with nOH to start Q1 2023.

## SEC filing metadata
- accession: 0001104659-22-115424
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465922115424/0001104659-22-115424-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465922115424/tm2229828d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-115424
- JSON: https://secwatch.observer/filing/0001104659-22-115424.json
- Plain text: https://secwatch.observer/filing/0001104659-22-115424.txt

## Key facts
- Earnings Releases
  Theravance Biopharma, Inc. reported third quarter of 2022 results: revenue $12.5 million.
  - Period: third quarter of 2022
  - Revenue: $12.5 million
  - Result: reported results
  source text: Revenue: Total revenue for the third quarter of 2022 was $12.5 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465922115424/0001104659-22-115424-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.